Dextrostix (Ames Co.) is a strip containing glucose oxidase, peroxidase, and a chromogen in a test pad. The colour generated provides a semiquantitative result if compared visually with the reference colours, interpolating between them as necessary. The range is 1 4-13 9 mmol/l (25-250 mg/100 ml).
SUMMARY Blood glucose levels were estimated in 101 neonatal blood samples using three glucose test strip methods and the results compared with those from a laboratory. BM-test-glycemie 20-800 test strips and Reflotest-hypoglycemie test strips gave a rapid and reliable estimate of blood glucose level in the range 0-8 mmol/l (0-140 mg/100 ml). Dextrostix test strips tended to overestimate all blood glucose levels.
It is important to detect hypoglycaemia in neonatal practice,' 2 The range is 0-55-8.3 mmol/l (10-150 mg/100 ml).
In the laboratory, blood glucose concentration was measured by either of two methods. The Technicon II autoanalyser uses glucose oxidase, peroxidase, and chromogen and separates glucose from plasma by dialysis. The Yellow Springs Glucose Analyser uses glucose oxidase and a peroxide electrode. The two methods agree closely on daily quality control checks.
The order in which Dextrostix and BM-testglycemie were performed was varied at random. They were both performed by the same observer before the other results were known.
Results
The Dextrostix, BM-test-glycemie, and Reflotest readings were plotted separately against the corresponding laboratory values (Figs 1, 2, and 3). It can be seen that Dextrostix tends to overestimate the blood glucose level. In five cases in this study Dextrostix failed to diagnose a laboratory level of less than 1-1 mmol/l (20 mg/100 ml) and in many instances it failed to indicate borderline hypoglycaemia. BM There is currently no standard approach to the management of immature or sick neonates with demonstrable coagulation abnormalities, but many authorities recommend that such infants be treated empirically with fresh frozen plasma (FFP) in the hope of preventing excessive damage from potential intracranial or intrapulmonary bleeding. However, there is no clinical evidence that this approach is reliably effective in reversing abnormal coagulation data in the neonate. In this study 23 infants with immaturity and mild to moderate respiratory distress syndrome received FFP in an attempt to support blood pressure. Prothrombin time (PT), activated partial thromboplastin time (PTT), quantitative platelet count, and levels of fibrinogen were determined before and after infusion to determine the effect of plasma on coagulation status in these infants.
Materials and methods
Babies studied. In our intensive care nursery FFP is sometimes used as a volume expander for attempted control of hypotension. We studied the effects of FFP infusions on the coagulation parameters in infants treated. Altogether 32 infants were studied within the first 48 hours of life. Nine infants were subsequently omitted from the study either because they demonstrated no abnormalities in coagulation studies before FFP infusion or because they had evidence of disseminated intravascular coagulation. All of the 23 patients remaining in the study survived. Gestational ages ranged from 28 to 38 weeks. Birthweights ranged from 965 to 4450 g. One infant was felt to be large for gestational age; none was judged to be small for gestational age. Twenty of the 23 infants had mild to moderate respiratory distress. PT, PTT, platelet count, and fibrinogen levels were determined in all infants before FFP infusion, and again 15 minutes after completion ofplasma infusion. All infants received FFP in a volume of 10 ml/kg. Laboratory methods. Whole blood, in a volume of 1.8 ml, was obtained by a 2-syringe technique through a 23-gauge scalp vein needle or through an indwelling umbilical artery catheter. Blood was transferred immediately to a tube containing buffered sodium citrate in a ratio of 9: 1. Plasma was separated at 4°C for 15 minutes at 10 000 rev/min. PT and PTT were done as previously described.' The concentration of fibrinogen was determined by microtechnique as described by Searcy et al. 2 Platelet counts were done by phase microscopy.
Results
Twenty-three infants with abnormally prolonged PT or PTT were treated with FFP in a dose of 10 ml/kg. 
